title: Prognostic indicators in fungemia of the surgical patient.
abstract: OBJECTIVE
  The objective of this study is to identify prognostic factors affecting mortality in surgical patients with culture-proved fungemia and to examine how amphotericin B affects mortality after controlling for these factors.
  
  
  METHODS
  The study is based on a retrospective logistic regression analysis of general surgical patients with blood cultures positive for fungi. We analyzed the patients' ages; whether they received triple antibiotics, had diabetes, had malignant neoplasia, received steroids, had concomitant bacteremia, or took antibiotics for greater than 7 days; and total dose of amphotericin B.
  
  
  METHODS
  The study was carried out at a university-based county hospital.
  
  
  METHODS
  Analysis of microbiology records for blood cultures that were positive for fungi from November 1987 to January 1992 revealed 63 general surgical patients. Patients with burns and those undergoing organ transplantation were excluded. Forty charts were complete and available for review.
  
  
  RESULTS
  Death was the outcome variable studied.
  
  
  RESULTS
  Stepwise logistic regression analysis of death revealed age to be a risk factor for mortality. Treatment with at least 210 mg of amphotericin B was associated with relative risk of death of 0.055.
  
  
  CONCLUSIONS
  Amphotericin B is effective even at low doses at decreasing the mortality in surgical patients with fungemia. On the other hand, increasing age is associated with an increased risk of mortality. Found not to be associated were concomitant bacteremia, concurrent triple antibiotic therapy, malignant neoplasia, and steroid use.
authors.affiliation: Department of Surgery, University of Southern California School of Medicine, Los Angeles.
authors.forename: E
authors.initials: E
authors.lastname: Tang
authors.forename: G
authors.initials: G
authors.lastname: Tang
authors.forename: T V
authors.initials: TV
authors.lastname: Berne
mesh_terms: D000367:Age Factors; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D006660:Histoplasmosis / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D000666:Amphotericin B